Skip to content

Return on assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
8.1%+2.5pp
Amgen logo
AmgenAMGN
8.6%+2.1pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-30.2%-5.5pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-34.3%+2.7pp
Erasca, Inc. logo
Erasca, Inc.ERAS
-59.4%+84.0pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-36.4%-3.4pp

Other financials

Income statement

See full
Revenue$6.6M
Operating income-$108.5M-28.6%
Net income-$98.5M-36.5%
EPS (diluted)-$1.11-35.4%

Balance sheet

See full
Cash & equivalents$157.5M+21.2%
Total debt$28.6M+10.1%
Total equity$937.3M-8.5%
Total assets$1.0B-6.4%

Cash flow

See full
Operating cash flow-$75.2M-24.6%
CapEx$967.0K-27.3%
Free cash flow-$76.1M-23.5%

Valuation

See full
Market cap$3.36B+104%
Enterprise value$3.23B+110%
P/S14.5×+9.9×

Profitability

See full
Operating margin-4,671.1%-5,434pp
Net margin-3,921.1%-4,562pp
FCF margin-3,592%-4,290pp

Returns & leverage

See full
Return on equity-14.3%-5.0pp
Debt / equity0.0×
Current ratio10.7×-3.2×

Where this comes from

Calculated from IDEAYA Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about IDEAYA Biosciences, Inc.'s return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is IDEAYA Biosciences, Inc.'s return on assets?
IDEAYA Biosciences, Inc. (IDYA) reported return on assets of -13.1% in Q1 2026.
How has IDEAYA Biosciences, Inc.'s return on assets changed year-over-year?
IDEAYA Biosciences, Inc.'s return on assets increased by 55.9% year-over-year, from -29.8% to -13.1%.
What is the long-term trend for IDEAYA Biosciences, Inc.'s return on assets?
Over 5 years (2020 to 2025), IDEAYA Biosciences, Inc.'s return on assets has grown at a -9.5% compound annual growth rate (CAGR), from -16.8% to -10.2%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.